Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Public ClinicalTrials.gov record NCT01652092. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
Study identification
- NCT ID
- NCT01652092
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 57 participants
Conditions and interventions
Conditions
- SCID
- Omenn's Syndrome
- Reticular Dysgenesis
- Wiskott-Aldrich Syndrome
- Bare Lymphocyte Syndrome
- Common Variable Immunodeficiency
- Chronic Granulomatous Disease
- CD40 Ligand Deficiency
- Hyper IgM Syndrome
- X-linked Lymphoproliferative Disease
- Hemophagocytic Lymphohistiocytosis
- Griscelli Syndrome
- Chediak-Higashi Syndrome
- Langerhan's Cell Histiocytosis
Interventions
- Alemtuzumab 0.3 mg Drug
- Cyclophosphamide Drug
- Busulfan Drug
- Stem Cell Transplantation Biological
- Fludarabine phosphate 40 mg Drug
- Melphalan Drug
- Alemtuzumab 0.2 mg Drug
- Fludarabine phosphate 30 mg Drug
- MESNA Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- Up to 50 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 3, 2012
- Primary completion
- Dec 29, 2025
- Completion
- Nov 30, 2026
- Last update posted
- Jun 16, 2026
2012 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Masonic Cancer Center, University of Minnesota | Minneapolis | Minnesota | 55455 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01652092, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01652092 live on ClinicalTrials.gov.